Cash round sets up trial of InteRNA’s microRNA for cancerDutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start Share XCash round sets up trial of InteRNA’s microRNA for cancerhttps://pharmaphorum.com/news/cash-round-sets-up-trial-of-internas-microrna-for-cancer/
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruitTwo years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a Share XNovo Nordisk’s gene silencing alliance with Dicerna bears first fruithttps://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/
New CEO Mortazavi takes UK biotech e-therapeutics into gene silencingUK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen Share XNew CEO Mortazavi takes UK biotech e-therapeutics into gene silencinghttps://pharmaphorum.com/news/new-ceo-mortazavi-takes-e-therapeutics-into-gene-silencing/
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcastAlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing Share XAlnylam, gene-silencing and biotech in 2020: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/alnylam-gene-silencing-biotech-2020/
Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
Alnylam gets CHMP backing for second gene-silencing drug GivlaariAlnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share XAlnylam gets CHMP backing for second gene-silencing drug Givlaarihttps://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
Alnylam gears up for first RNAi therapeutic filing in 2017US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what Share XAlnylam gears up for first RNAi therapeutic filing in 2017https://pharmaphorum.com/news/alnylam-gears-up-for-first-rnai-therapeutic-filing-in-2017/
